RGRN-305 is under clinical development by Regranion and currently in Phase I for Hidradenitis Suppurativa. According to GlobalData, Phase I drugs for Hidradenitis Suppurativa have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RGRN-305’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RGRN-305 overview

RGRN-305 (CUDC-305) is under development for the treatment of plaque psoriasis, bullous pemphigoid, hidradenitis suppurativa, atopic dermatitis. The drug candidate is administered topically and orally . It was under development for the treatment of  non-small cell lung cancer, metastatic renal cell carcinoma and lymphomas. It is a synthetic small molecule that acts by targeting heat shock protein 90 (Hsp90). It is developed based on Heat Shock Protein (Hsp90) technology.

For a complete picture of RGRN-305’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.